{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:14:08Z","timestamp":1784229248574,"version":"3.55.0"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Guidelines for the treatment of sepsis, febrile neutropenia, and hospital-acquired pneumonia caused by\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            include empirical regimens incorporating two antibiotics from different classes with activity against\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            for select at-risk patients to increase the likelihood that the organism will be susceptible to at least one agent. The activity against\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            and the rates of cross-resistance of ceftolozane-tazobactam were compared to those of the \u03b2-lactam comparators cefepime, ceftazidime, piperacillin-tazobactam, and meropenem alone and cumulatively with ciprofloxacin or tobramycin. Nonurine\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            isolates were collected from adult inpatients at 44 geographically diverse U.S. hospitals. MICs were determined using reference broth microdilution methods. Of the 1,257 isolates collected, 29% were from patients in intensive care units and 39% were from respiratory sites. The overall rate of susceptibility to ceftolozane-tazobactam was high at 97%, whereas it was 72 to 76% for cefepime, ceftazidime, piperacillin-tazobactam, and meropenem. The rate of nonsusceptibility to all four comparator \u03b2-lactams was 11%; of the isolates nonsusceptible to the four comparator \u03b2-lactams, 80% remained susceptible to ceftolozane-tazobactam. Among the isolates nonsusceptible to the tested \u03b2-lactam comparators, less than half were susceptible to ciprofloxacin. By comparison, approximately 80% of the \u03b2-lactam-nonsusceptible isolates were susceptible to tobramycin, for overall cumulative susceptibility rates of 94 to 95%, nearly 10% higher than that of the ciprofloxacin\u2013\u03b2-lactam combinations and approaching that of ceftolozane-tazobactam as a single agent. The rates of susceptibility to ceftolozane-tazobactam were consistently high, with little observable cross-resistance. Ceftolozane-tazobactam monotherapy performed at or above the level of commonly utilized combination therapies on the basis of\n            <jats:italic>in vitro<\/jats:italic>\n            susceptibilities. Ceftolozane-tazobactam should be considered for use in patients at high risk for resistant\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            infection and as an alternative to empirical combination therapy, especially for patients unable to tolerate aminoglycosides.\n          <\/jats:p>","DOI":"10.1128\/aac.01350-17","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T00:40:23Z","timestamp":1505781623000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":32,"title":["<i>In Vitro<\/i>\n            Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa"],"prefix":"10.1128","volume":"61","author":[{"given":"Kellie J.","family":"Goodlet","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Nailor","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hartford Hospital, Hartford, Connecticut, USA"},{"name":"University of Connecticut School of Pharmacy, Storrs, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/668770"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.11.025"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/501795"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70258-9"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00040-09"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01802-13"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.12.012"},{"key":"e_1_3_2_9_2","volume-title":"Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","author":"European Centre for Disease Prevention and Control","year":"2017","unstructured":"European Centre for Disease Prevention and Control. 2017. Antimicrobial resistance surveillance in Europe 2015. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). European Centre for Disease Prevention and Control,Stockholm, Sweden."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03672.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq147"},{"key":"e_1_3_2_13_2","volume-title":"NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections, version 2","author":"Baden LR","year":"2017","unstructured":"Baden LR SwaminathanSAngaroneMBlouinGCasperCCooperBDubberkeEREngemannAMFreifeldAGGreeneJNGreggKHakimHItoJILustbergMEMontoyaJGRolstonKSatyanarayanaGSchulzLSegalBSeoSKShohamSTaplitzRTupalJWilsonJW. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections, version 2.2017. National Comprehensive Cancer Network,Washington, PA."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.091025"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis803"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ482"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002255"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.11.1073"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.2756-2764.2003"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001340000640"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1116"},{"key":"e_1_3_2_22_2","first-page":"51","article-title":"Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime\/ceftazidime susceptibility profiles","volume":"1","author":"Laohavaleeson S","year":"2008","unstructured":"Laohavaleeson S LolansKQuinnJPKutiJLNicolauDP. 2008. Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime\/ceftazidime susceptibility profiles. Infect Drug Resist1:51\u201355.","journal-title":"Infect Drug Resist"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02462-13"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00825-15"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.174"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/653053"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01365-09"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015625658"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix014"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.05.501"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01350-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01350-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:45:25Z","timestamp":1645476325000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01350-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1128\/AAC.01350-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01350-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"2017-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01350-17"}}